St. Paul, Minn.– Medical technology startup SecondWave Systems has raised $7 million in a Series A funding round to further develop its innovative ultrasound-based therapy for inflammatory disorders. The round was co-led by Treo Ventures and a major strategic healthcare investor, with additional participation from Scientific Health Development and the University of Minnesota’s Discovery Capital and SSBCI funds.
The new investment will fund an upcoming clinical study, following promising results from SecondWave’s first-in-human trial, which showed a significant reduction in rheumatoid arthritis symptoms using its wearable device, the SecondWave MINI™.
The MINI™ is a first-of-its-kind, noninvasive therapeutic ultrasound device designed to treat immune-mediated inflammatory diseases. The company previously received research and development support from U.S. government agencies including the Defense Advanced Research Projects Agency (DARPA) and the Advanced Research Projects Agency for Health (ARPA-H).
“With this new funding, we’re entering a pivotal phase in bringing a new class of noninvasive therapy to patients,” said SecondWave CEO Anuj Bhardwaj. “Our goal is to improve quality of life for millions living with chronic inflammatory conditions.”
Treo Ventures General Partner Mudit K. Jain, PhD, highlighted the potential impact of the technology: “We’re excited to partner with SecondWave to advance a differentiated, cost-effective therapy that could transform care for patients worldwide.”
Paul Peter Tak, MD, PhD, a member of SecondWave’s advisory board and a pioneer in bioelectronic medicine, also praised the company’s direction. “SecondWave’s ultrasound-based therapy represents a major step forward in treating autoimmune diseases without the need for implants,” he said.
With its latest funding and growing support from both private and public sectors, SecondWave is positioning itself as a key player in the evolving field of bioelectronic and noninvasive medicine.
